Elanco Animal Health announced the approval of Imrestor™ (pegbovigrastim injection) – the first product of its kind for the dairy industry. Available only by veterinary prescription, Imrestor is now FDA approved for the reduction in the incidence of clinical mastitis in the first 30 days of lactation in periparturient dairy cows and periparturient replacement dairy heifers. Imrestor is a protein that helps support the natural function of a dairy cow’s immune system during the critical time around calving, when she is most vulnerable to mastitis. “Imrestor is an innovative new approach for reducing clinical mastitis by proactively helping to restore the function of a cow’s immune system,” explained Paul Rapnicki, DVM, MBA, Associate Technical Advisor, Elanco Animal Health.
Pivotal efficacy studies conducted for FDA approval showed a 28 percent reduction in clinical mastitisincidence among cows and heifers that received Imrestor compared with control animals.1 Mastitis is the most common disease among dairy cows, affecting as many as 1 in 4 cows.2 Clinical mastitis affects each cow’s potential leading to reduced conception rates3, an increased risk for another case of mastitis4, and lost milk production potential throughout the lactation5.